Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

NCT02672358 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Company Decision

Conditions

Non-Small-Cell Lung Cancer

Interventions

DRUG: Dabrafenib
DRUG: Trametinib

Sponsor

Novartis Pharmaceuticals